PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...
Adding hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C to surgery for locally advanced colorectal cancer (CRC) significantly reduced the risk of locoregional recurrence, the ...
The median number of BCG doses per patient was 9 in the combination arm and 16 in the monotherapy arm. Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback